Cargando…
Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan
OBJECTIVES: To evaluate the effectiveness of remdesivir in the early stage of nonsevere COVID-19. Although several randomized controlled trials have compared the effectiveness of remdesivir with that of a placebo, there is limited evidence regarding its effect in the early stage of nonsevere COVID-1...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857764/ https://www.ncbi.nlm.nih.gov/pubmed/35192953 http://dx.doi.org/10.1016/j.ijid.2022.02.039 |
_version_ | 1784654108795338752 |
---|---|
author | Tsuzuki, Shinya Hayakawa, Kayoko Uemura, Yukari Shinozaki, Tomohiro Matsunaga, Nobuaki Terada, Mari Suzuki, Setsuko Asai, Yusuke Kitajima, Koji Saito, Sho Yamada, Gen Shibata, Taro Kondo, Masashi Izumi, Kazuo Hojo, Masayuki Mizoue, Tetsuya Yokota, Kazuhisa Nakamura-Uchiyama, Fukumi Saito, Fumitake Sugiura, Wataru Ohmagari, Norio |
author_facet | Tsuzuki, Shinya Hayakawa, Kayoko Uemura, Yukari Shinozaki, Tomohiro Matsunaga, Nobuaki Terada, Mari Suzuki, Setsuko Asai, Yusuke Kitajima, Koji Saito, Sho Yamada, Gen Shibata, Taro Kondo, Masashi Izumi, Kazuo Hojo, Masayuki Mizoue, Tetsuya Yokota, Kazuhisa Nakamura-Uchiyama, Fukumi Saito, Fumitake Sugiura, Wataru Ohmagari, Norio |
author_sort | Tsuzuki, Shinya |
collection | PubMed |
description | OBJECTIVES: To evaluate the effectiveness of remdesivir in the early stage of nonsevere COVID-19. Although several randomized controlled trials have compared the effectiveness of remdesivir with that of a placebo, there is limited evidence regarding its effect in the early stage of nonsevere COVID-19 cases. METHODS: We evaluated the effectiveness of remdesivir in the early stage of nonsevere COVID-19 using the COVID-19 Registry Japan, a nationwide registry of hospitalized patients with COVID-19 in Japan. Two regimens (“start remdesivir” therapy within 4 days from admission versus no remdesivir during hospitalization) among patients without the need for supplementary oxygen therapy were compared by a 3-step processing (cloning, censoring, and weighting) method. The primary outcome was a supplementary oxygen requirement during hospitalization. Secondary outcomes were 30-day in-hospital mortality and the risk of invasive mechanical ventilation or extracorporeal membrane oxygenation (IMV/ECMO). The data of 12,487 cases met our inclusion criteria. The “start remdesivir” regimen showed a lower risk of supplementary oxygen requirement (hazard ratio [HR]: 0.850, 95% confidence interval [CI]: 0.798–0.906, p value < 0.001). Both 30-day in-hospital mortality and risk of IMV/ECMO introduction were not significantly different between the 2 regimens (HRs: 1.04 and 0.983, 95% CI: 0.980–1.09 and 0.906–1.07, p values: 0.210 and 0.678, respectively). CONCLUSIONS: Remdesivir might reduce the risk of oxygen requirement during hospitalization in the early stage of COVID-19; however, it had no positive effect on the clinical outcome and reduction in IMV/ECMO requirement. |
format | Online Article Text |
id | pubmed-8857764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88577642022-02-22 Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan Tsuzuki, Shinya Hayakawa, Kayoko Uemura, Yukari Shinozaki, Tomohiro Matsunaga, Nobuaki Terada, Mari Suzuki, Setsuko Asai, Yusuke Kitajima, Koji Saito, Sho Yamada, Gen Shibata, Taro Kondo, Masashi Izumi, Kazuo Hojo, Masayuki Mizoue, Tetsuya Yokota, Kazuhisa Nakamura-Uchiyama, Fukumi Saito, Fumitake Sugiura, Wataru Ohmagari, Norio Int J Infect Dis Article OBJECTIVES: To evaluate the effectiveness of remdesivir in the early stage of nonsevere COVID-19. Although several randomized controlled trials have compared the effectiveness of remdesivir with that of a placebo, there is limited evidence regarding its effect in the early stage of nonsevere COVID-19 cases. METHODS: We evaluated the effectiveness of remdesivir in the early stage of nonsevere COVID-19 using the COVID-19 Registry Japan, a nationwide registry of hospitalized patients with COVID-19 in Japan. Two regimens (“start remdesivir” therapy within 4 days from admission versus no remdesivir during hospitalization) among patients without the need for supplementary oxygen therapy were compared by a 3-step processing (cloning, censoring, and weighting) method. The primary outcome was a supplementary oxygen requirement during hospitalization. Secondary outcomes were 30-day in-hospital mortality and the risk of invasive mechanical ventilation or extracorporeal membrane oxygenation (IMV/ECMO). The data of 12,487 cases met our inclusion criteria. The “start remdesivir” regimen showed a lower risk of supplementary oxygen requirement (hazard ratio [HR]: 0.850, 95% confidence interval [CI]: 0.798–0.906, p value < 0.001). Both 30-day in-hospital mortality and risk of IMV/ECMO introduction were not significantly different between the 2 regimens (HRs: 1.04 and 0.983, 95% CI: 0.980–1.09 and 0.906–1.07, p values: 0.210 and 0.678, respectively). CONCLUSIONS: Remdesivir might reduce the risk of oxygen requirement during hospitalization in the early stage of COVID-19; however, it had no positive effect on the clinical outcome and reduction in IMV/ECMO requirement. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-05 2022-02-19 /pmc/articles/PMC8857764/ /pubmed/35192953 http://dx.doi.org/10.1016/j.ijid.2022.02.039 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Tsuzuki, Shinya Hayakawa, Kayoko Uemura, Yukari Shinozaki, Tomohiro Matsunaga, Nobuaki Terada, Mari Suzuki, Setsuko Asai, Yusuke Kitajima, Koji Saito, Sho Yamada, Gen Shibata, Taro Kondo, Masashi Izumi, Kazuo Hojo, Masayuki Mizoue, Tetsuya Yokota, Kazuhisa Nakamura-Uchiyama, Fukumi Saito, Fumitake Sugiura, Wataru Ohmagari, Norio Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan |
title | Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan |
title_full | Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan |
title_fullStr | Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan |
title_full_unstemmed | Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan |
title_short | Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan |
title_sort | effectiveness of remdesivir in hospitalized nonsevere patients with covid-19 in japan: a large observational study using the covid-19 registry japan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857764/ https://www.ncbi.nlm.nih.gov/pubmed/35192953 http://dx.doi.org/10.1016/j.ijid.2022.02.039 |
work_keys_str_mv | AT tsuzukishinya effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT hayakawakayoko effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT uemurayukari effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT shinozakitomohiro effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT matsunaganobuaki effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT teradamari effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT suzukisetsuko effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT asaiyusuke effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT kitajimakoji effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT saitosho effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT yamadagen effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT shibatataro effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT kondomasashi effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT izumikazuo effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT hojomasayuki effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT mizouetetsuya effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT yokotakazuhisa effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT nakamurauchiyamafukumi effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT saitofumitake effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT sugiurawataru effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan AT ohmagarinorio effectivenessofremdesivirinhospitalizednonseverepatientswithcovid19injapanalargeobservationalstudyusingthecovid19registryjapan |